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The vast majority of clinically approved protein kinase inhibitors target the
ATP-binding pocket directly. Consequently, many inhibitors have broad selec-
tivity profiles and most have significant off-target effects. Allosteric inhibitors
are generallymore selective, but are difficult to identify because allosteric bind-
ing sites are often unknown or poorly characterized. Aurora-A is activated
through binding of TPX2 to an allosteric site on the kinase catalytic domain,
and this knowledge could be exploited to generate an inhibitor. Here, we gen-
erated an allosteric inhibitor of Aurora-A kinase based on a synthetic, vNAR
single domain scaffold, vNAR-D01. Biochemical studies and a crystal structure
of the Aurora-A/vNAR-D01 complex show that the vNAR domain overlaps
with the TPX2 binding site. In contrast with the binding of TPX2, which stabil-
izes an active conformation of the kinase, binding of the vNAR domain
stabilizes an inactive conformation, inwhich the aC-helix is distorted, the cano-
nical Lys-Glu salt bridge is broken and the regulatory (R-) spine is disrupted by
an additional hydrophobic side chain from the activation loop. These studies
illustrate how single domain antibodies can be used to characterize the regulat-
ory mechanisms of kinases and provide a rational basis for structure-guided
design of allosteric Aurora-A kinase inhibitors.1. Introduction
Kinase mutations drive many cancers through deregulated activity, and inhibi-
tors of these kinases have revolutionized cancer treatment. Most current kinase
inhibitors target the ATP-binding site, which is relatively straightforward to
block with small molecules [1]. However, this site is also highly conserved
among all protein kinases, and therefore many inhibitors have off-target effects.
Patients treated with kinase inhibitors inevitably relapse due to drug resistance
mechanisms such as kinase overexpression, mutation or the activation of
bypass pathways, usually involving other kinases. Complex tumour biology,
including genetic heterogeneity and drug resistance, may require the inhibition
of more than one kinase for effective therapy [2–4]. Combinations of kinase
inhibitors might address these issues, but combining these drugs safely and
effectively is a challenge. This is thought to be, at least to some extent, due to
the unfocused selectivity profiles of ATP-competitive inhibitors. Kinase inhibi-
tors that bind to allosteric sites are more selective than ATP-competitive
inhibitors [5]. However, allosteric inhibitors are more challenging to develop
because kinase targets do not always have a clearly suitable allosteric site, and
approaches to targeting such sites through screening and synthetic chemistry
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2are less well developed than for the ATP-binding site. As a con-
sequence, there are few examples of allosteric kinase inhibitors
in the clinic. More recently, there have been several rational
approaches to the development of allosteric inhibitors, which
require foreknowledge of suitable binding sites [6–8].
Aurora-A is a Ser/Thr protein kinase that functions pri-
marily in cell division and is overexpressed in breast, colon
and other cancers [9]. Aurora-A interacts with and stabilizes
N-Myc and c-Myc, transcription factors that underpin cancer
development [10,11]. Consequently, ATP-competitive inhibi-
tors of Aurora-A are under investigation in the treatment of
neuroblastoma, a childhood cancer of the nervous system
that is largely driven by N-Myc [12]. The activity of
Aurora-A is stimulated by autophosphorylation of Thr288
in a flexible region termed the activation loop [13]. Aurora-
A autophosphorylation is inefficient, but is stimulated
by TPX2, a microtubule-associated protein that binds to the
catalytic domain and stabilizes the kinase in an active confor-
mation [14–17]. TPX2 binds to Aurora-A at two sites,
stabilizing the positions of the aC-helix and activation loop
through a structural mechanism that resembles the function
of N- and C-terminal extensions present in AGC family
kinases such as PKA [17]. Aurora-A is dysregulated in
cancers and has been a popular target for drug discovery
[9,18]. The first ATP-competitive inhibitors generated were
equally effective against Aurora-B, but there are now a
few compounds selective for Aurora-A that have undergone
clinical trials, such as MLN8054 and MLN8237 [19,20]. To our
knowledge, allosteric inhibitors of Aurora-A have not yet
been identified and there has been no clearly described plan
for their development. One potential approach to allosteric
Aurora-A inhibitors would be to block the interaction with
TPX2. However, a small molecule or peptide that mimics the
binding of TPX2 to Aurora-A would be expected to stabilize
the active conformation through the same mechanism as
TPX2. A more effective strategy might be to develop inhibitors
that stabilize an inactive conformation of Aurora-A.
In addition to conventional antibodies, camelids and car-
tilaginous fish (e.g. sharks, rays and skates) have antibodies
that consist of a homodimer of two heavy chains [21–23].
For example, the immunoglobin new antigen receptor
(IgNAR) from sharks consists of a heavy chain comprising
five constant (C) domains and a single, variable domain,
termed V or vNAR that binds targets. vNAR domains have
an Ig fold consisting of only eight b-strands, in which the
CDR2 region of a conventional VH domain is replaced by a
short b-strand HV2 [24,25]. Camelid heavy chain antibodies
also recognize epitopes through a single variable VHH
domain. Distinct from the equivalent VH domain of conven-
tional antibodies, the variable domains of heavy chain
antibodies are independently stable and retain high affinity
for epitope [23]. Single domain antibodies, also known as nano-
bodies, have becomepopular tools to stabilize proteins and thus
facilitate their crystallization, and probe cryptic epitope sites
[26–29]. Single domain antibodies have also been used as bio-
technological tools to improve the pharmacokinetic properties
of therapeutic fusion partners [30].
Here, we describe the identification of a vNAR single
domain antibody based on a shark heavy chain antibody
scaffold that binds and inhibits Aurora-A. The crystal
structure of the complex indicates an allosteric mode
of action that is antagonistic to the mechanism by which
TPX2 activates the kinase. These studies provide a rationalbasis for structure-guided design of allosteric Aurora-A
kinase inhibitors.2. Results
2.1. Identification of a single domain antibody that
inhibits Aurora-A
A synthetic library of vNAR domains based on a scaffold iso-
lated from Wobbegong shark was screened for binding to the
kinase domain (KD) of human wild-type (WT) Aurora-A.
All of the confirmed hits had the same amino acid sequence
(electronic supplementary material, figure S1A). This protein,
whichwe called vNAR-D01, was expressed in the periplasm of
Escherichia coli with a non-cleavable C-terminal His6-tag, and
purified using affinity and size exclusion chromatography
(SEC). vNAR-D01 was verified to bind Aurora-A by far wes-
tern blotting and SEC (electronic supplementary material,
figures S1b and S2). Binding was not dependent on the phos-
phorylation status of the kinase (electronic supplementary
material, figure S1b). The affinity of the interaction was deter-
mined to be 2 mM by surface plasmon resonance (SPR)
(figure 1a; electronic supplementary material, figure S3a).
We investigated whether vNAR-D01 affected the inter-
action of Aurora-A with TPX2 using nickel sepharose to
precipitate protein complexes through association with the
His6-tag attached to a single component (figure 1b). Aurora-
A KD C290A, C393A (CA) was used as this mutant routinely
generates crystals of higher resolution than the WT KD [31].
Here, untagged Aurora-A KD CA was efficiently co-precipi-
tated by vNAR-D01, but GST-TPX21–43 did not co-precipitate
with the complex. By contrast, GST-TPX21–43 was efficiently
precipitated by His6-tagged Aurora-A KD CA in the absence
of the vNAR domain. This suggested competition between
TPX2 and vNAR-D01 for Aurora-A binding. His6-TPX2
1–43
or vNAR-D01 robustly co-precipitated with GST-Aurora-A
KD D274N (DN; the mutation results in a catalytically inactive
form of the kinase) immobilized on Glutathione Sepharose
beads, but competition was established through a dose-depen-
dent decrease in vNAR-D01 binding as the concentration
of TPX2 was increased (figure 1c). We used Xenopus egg
extracts to investigate the competition between vNAR-D01
and Aurora-A in a situation closer to the physiological
pathway (electronic supplementary material, figure S3b).
In this system, TPX2 and Aurora-A robustly interact when
extracts are supplemented with RanGTP [14]. However, co-
precipitation of vNAR-D01 with Xenopus Aurora-A was not
observed and we concluded that we would require a vNAR
domain of higher binding affinity and/or generated against
the Xenopus protein to warrant further investigation.
In light of the competition between vNAR-D01 and
the Aurora-A activator, TPX21–43, we asked whether vNAR-
D01 might also activate the kinase. vNAR-D01 was added
to kinase assays based on incorporation of 32P into a substrate
protein to quantify the kinase activity of Aurora-A (figure 1d,e).
vNAR-D01 showed a dose-dependent inhibition of Aurora-A,
an effect opposite to that of TPX2. To address the mechanism
of Aurora-A inhibition by vNAR-D01, we crystallized the
complex in two different forms and determined the structu-
res by X-ray crystallography to limiting resolutions of 1.67 A˚
and 1.79 A˚, respectively (electronic supplementary material,
table S1). In both crystal forms the asymmetric unit contained
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Figure 1. (Caption overleaf.)
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3a single complex of Aurora-A KD CA/vNAR-D01 with a 1 : 1
stoichiometry. The two crystal structures are very similar,
with an overall Ca RMSD of 0.97 A˚ (electronicsupplementary material, figure S4). ADP is bound in the
ATP-binding pocket but there are no magnesium ions present
in the active site of either structure, and the side chain
Figure 1. (Overleaf.) vNAR-D01 is an Aurora-A inhibitor that competes with TPX2. (a) Surface plasmon resonance binding assays between Aurora-A KD CA-Avi and
vNAR-D01. The kinase was immobilized on Biacore Sensor SA chips at 550, 350 and 250 RU and interacted with 0.01–50 mM vNAR-D01. Maximum responses were
plotted against vNAR-D01 concentration and fitted to a one-site specific binding equation (solid lines) in PRISM6 (GraphPad) to calculate binding affinities. (b) Co-
precipitation assay between the Aurora-A KD CA/vNAR-D01 complex or His6-Aurora-A KD CA and GST-TPX2
1– 43. The complex and Aurora-A were immobilized on
Nickel Sepharose beads using the His6-tag on the vNAR domain and kinase, respectively. GST was used as a binding control. (c) Co-precipitation assay between GST-
Aurora-A KD DN and vNAR-D01 and His6-TPX2
1– 43. In total, 2 mM GST-Aurora-A KD DN was immobilized on Glutathione Sepharose 4B beads and incubated with
5 mM vNAR-D01 and 0, 1, 2, 5, 10, 20 and 50 mM His6-TPX2 (black triangle). GST was used as a binding control. (d ) In vitro kinase activity assay of Aurora-A KD in
the presence of vNAR-D01. MBP was used as a generic kinase substrate. Reactions were analysed by SDS-PAGE (top left panel) and incorporation of radioisotope
resolved by autoradiography (bottom left panel). Incorporation of radioisotope was measured by scintillation counting (right). Error bars represent the standard error
for two independent reactions. ** ¼ p, 0.01, *** ¼ p, 0.001 and **** ¼ p, 0.0001 using one-way ANOVA with Dunnett’s post hoc test compared with the
kinase only reaction. (e) In vitro kinase activity curves of Aurora-A KD in the presence of WT and mutant vNAR-D01 proteins. The kinase activity of Aurora-A KD was
measured by the incorporation of radioisotope into the generic kinase substrate, MBP by scintillation counting in the presence of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50 and
100 mM vNAR-D01. Data were normalized to % kinase activity using the Aurora-A KD only reaction as 100% and plotted against vNAR-D01 concentration (right).
Data were fitted to a log(inhibitor) versus response—variable slope in PRISM6 (GraphPad) to calculate IC50s (right, solid line). n.s. ¼ no significant inhibition
observed.
rsob.royalsocietypublishing.org
Open
Biol.6:160089
4of Asp274, which coordinates magnesium ions in other
Aurora-A structures, is displaced from the active site and
instead interacts with the side chain of His254.
2.2. The binding sites of vNAR-D01 and TPX2
on Aurora-A overlap
In the crystal structure of the complex,Aurora-A adopts a cano-
nical kinase fold, with amolecule of ADP sandwiched between
the N- and C-lobe (figure 2a). vNAR-D01 has an Ig fold with
two disulfide bridges. vNAR-D01 makes contacts with both
lobes of Aurora-A, but does not closely approach the ATP-
binding pocket. The interface is centred on the aC-helix
within the N-lobe of Aurora-A. This helix within the kinase
fold bears residues that are critical for catalysis and is often
the site of interactions with regulatory binding partners as
exemplified by the complex of Cyclin-A/CDK2 and TPX2/
Aurora-A (figure 2b).
The interface of the complex buries 950 A˚2 of surface mol-
ecule per molecule of vNAR-D01 or Aurora-A. The binding
footprint of vNAR-D01 on Aurora-A comprises regions of
the aC-helix, b4 strand, activation loop and the N-terminus
of helix aE (figure 2c). All three variable regions of vNAR-
D01 contact the kinase surface: Asp33 from CDR1 forms a
salt bridge with Arg179 (Aurora-A aC); residues 48–49 of
HV2 contact the N-terminus of aE; Ser51 (main chain only)
and Ile52 (main chain and side chain) of HV2 interact with
the activation loop sequence Val279-His280-Ala281; the side
chains of CDR3 residues Ile87 and Trp91 insert into a hydro-
phobic pocket formed between aC and b4; and the Trp91
side chain makes an H-bond with the Glu175 side chain
within this pocket (figure 3a). In addition, Asn36 and Tyr38
from bC interact with the aC-helix through an H-bond with
the side chain of Glu183 (and van der Waals contact with the
side chain of His187). These interactions are mostly conserved
between the two crystal forms of the complex, with the excep-
tion of the contacts between HV2 and activation loop
(electronic supplementary material, figure S4d ). The binding
conformation of vNAR-D01 is probably stabilized by a non-
canonical disulfide bond between Cys30 of CDR1 and Cys90
CDR3, a characteristic feature of type II/III vNAR domains
(figure 2a; electronic supplementary material, figure S1A) [32].
To validate the crystal structure, we generated a point
mutation in vNAR-D01, W91A, designed to disrupt the
interaction. We also generated a series of mutations withthe aim of enhancing the interaction: Q48E, T49Q, S51D,
S51N, S93 K and S93R. All mutant vNAR-D01 proteins were
expressed and purified, and tested for binding to Aurora-A
by co-precipitation assay (figure 3b). As predicted, the W91A
mutation completely disrupted the interaction and the other
mutants retained binding. The circular dichroism (CD) spec-
trum of WT vNAR-D01 and the W91A mutant were similar,
indicating no changes in secondary structure resulted from
mutation (electronic supplementary material, figure S5).
We then determined the potency of Aurora-A inhibition by
vNAR-D01 and the point mutants using a kinase assay in
which vNAR-D01 inhibited Aurora-A with a IC50 of 6.76 mM
(figure 1e; electronic supplementary material, figure S6a). We
could not detect any inhibition of Aurora-A by the W91A
mutant vNAR-D01, consistent with the loss of interaction.
Three of the other mutants exhibited less potent inhibition:
Q48E, T49Q and S51D. Three of the mutants exhibited more
potent inhibition: S51N, S93 K and S93R. The most potent
inhibitor was S93R-vNAR-D01, with an IC50 of 3.02 mM
(figure 1e; electronic supplementary material, figure S6a). A
crystal structure of S93R-vNAR-D01 showed only a minor
change in conformation from vNAR-D01: the side chain
of Arg93 forms an intramolecular salt bridge with Glu95
(electronic supplementary material, figure S6b).2.3. vNAR-D01 destabilizes the aC-helix of Aurora-A
The conformation of Aurora-A in complex with vNAR-D01
lacks key hallmarks of an active kinase: there is no Lys-Glu
salt bridge and the hydrophobic R-spine is incorrectly
formed (figure 4a). In its active conformation, when bound to
TPX2, the kinase has a salt bridge between Lys162 and
Glu181, and the R-spine is correctly assembled by the inter-
actions between the side chains of Leu196, Gln185, Phe275
and His254 (figure 4b) [17,33,34]. Indeed, the R-spine of
Aurora-A in complexwith vNAR-D01 is disrupted by the pres-
ence of an additional side chain: Trp277, which is predicted to
interact with substrate peptide in the active kinase, is twisted
inwards and fills the space that Phe275 (of the DFG-motif)
would normally occupy. Phe275 is displaced to a position
between Lys162 and Glu181. Trp277 also H-bonds with
Gln185, twisting this R-spine component out of position.
These conformational changes are coupled to a distortion of
the aC-helix in the vicinity of Glu181. The distortion is stabil-
ized by interactions on all sides: the side closest to b4 is
CDR3
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HV2aC
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b5
activation
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Aurora-A vNAR-D01
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CDK2
CycA
Aurora-A
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Aurora-A vNAR-D01
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(b)(a)
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Figure 2. Crystal structure of Aurora-A/vNAR-D01 complex. (a) Cartoon representation of the complex structure (crystal form 1). Aurora-A is coloured teal and vNAR-
D01 is coloured orange. (b) Structures of CDK2/Cyclin-A (PDB 1FIN) and Aurora-A/TPX2 (PDB 1OL5) complexes. The aC-helix is marked with a black rectangle in
panels (a) and (b). (c) The interacting regions of the Aurora-A and vNAR-D01 are shown as contrasting colours on the individual proteins (yellow and green,
respectively).
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5stabilized by Trp91 of vNAR-D01 CDR3; the side facing out to
solution is stabilized byAsp33, Asn36 andTyr38 of vNAR-D01
CDR1 and strand bC; and the inside is stabilized by confor-
mational changes in the activation loop, most notably Phe275
and Trp277. The position of the aC-helix is incompatible
with TPX2 binding, as side chains of Glu175 and Arg179
would clash with Tyr8 and Tyr10 (figure 4c). In summary,
TPX2 stabilizes the active conformation of Aurora-A and
vNAR-D01 stabilizes an inactive conformation (a schematic
overview is shown in figure 4d ).
The conformation of Aurora-A bound to vNAR-D01 bears
a striking resemblance to Aurora-A in complex with
MLN8054, an ATP-competitive inhibitor that induces confor-
mational changes in the catalytic domain (figure 5a) [19,35].
MLN8054 interacts extensively with the DFG-motif and
causes a substantial conformational change in the activation
loop. MLN8054 and vNAR-D01 both stabilize a distortion
in the aC-helix that disrupts the Lys-Glu salt bridge by
moving the side chain of Glu181 away from the ATP-binding
site. The distortion of the aC-helix is coupled to a shift in the
position of the side chain of Phe275, which fills the space
vacated by Glu181 (figure 5b,c). Therefore, the mechanism
by which vNAR-D01 inhibits Aurora-A recapitulates some
of the features of MLN8054, without blocking the bindingof ATP. Furthermore, the conformation of Aurora-A trapped
by vNAR-D01 is also similar to that observed for Aurora-A in
complex with adenosine (figure 5d ) [36]. Thus, three struc-
tures of Aurora-A exhibit a distorted aC-helix coupled to
changes in the position of Phe275, which represent three dis-
tinct complexes of the kinase crystallized under three different
conditions. It therefore seems likely that the conserved features
of these structures represent a physiologically relevant confor-
mation of Aurora-A, one of many that may exist when the
kinase is in a dynamic state, which can be captured by ligands
or vNAR-D01.3. Discussion
3.1. Single domain antibodies as tools to manipulate
kinase structure and activity
One attraction of targeting allosteric sites is that they are more
or less unique to an individual kinase, and therefore allosteric
inhibitors are potentially more selective than ATP-competitive
inhibitors. Among human protein kinases, the three residues
that contact Trp91 of vNAR-D01 (Asp175, Arg179 and
Val206) are identical only in Aurora-C, and only Aurora-B
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induces a rearrangement of the activation loop. (d ) Superposed structures of Aurora-A in complex with vNAR-D01/ADP (teal) and adenosine (lilac).
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7has a single conservative substitution (Ile in place of Val206).
All other human protein kinases have at least one non-
conserved residue, and of these, the pairing of an acidic
residue/basic residue at the positions equivalent to Asp175
and Arg179 is found only in kinase interacting with stathmin
(KIS) [37]. vNAR-D01 is likely to be specific to the Aurora
kinase family, with the possible exception of KIS. However,
we have not yet carried out a biochemical study of the speci-
ficity of vNAR-D01, which would be necessary to support
this bioinformatical analysis.
Previouswork showed that single domain antibodies could
be used to trap a kinase in a specific conformation and modu-
late kinase activity through binding to a regulatory domain
[38,39]. Structures of cyclin-G associated kinase (GAK) in two
different conformations were captured by co-crystallization
with two nanobodies (NbGAK_1 and NbGAK_4), which
bind to two different regions of the kinase surface, both of
which are distinct from thosewe observed for vNAR-D01 (elec-
tronic supplementary material, figure S7) [38]. In complex
with NbGAK_1, GAKwas monomeric with an ordered activa-
tion loop, whereas NbGAK_4 trapped a dimeric configuration
with disordered activation loops. Despite the differencesobserved in the crystal structures, the nanobodies had very
little effect on GAK activity in solution: NbGAK_4 modes-
tly enhanced kinase activity, while NbGAK_1 had no effect.
Toxoplasma gondii Calcium-dependent protein kinase 1
(TgCDPK1) consists of a catalytic domain and a regulatory
domain that either inhibits or promotes kinase activity in
response to calcium. A single domain VHH antibody that
interacts with the regulatory domain of TgCDPK1 (1B7) inhi-
bits the kinase by stabilizing the regulatory domain in the
inhibitory conformation [39]. These two studies illustra-
ted the potential of nanobodies as tools for biochemical and
structural analysis of kinases. Here, we show that the single
domain antibody vNAR-D01 binds directly to the catalytic
domain of Aurora-A and inhibits kinase activity through
an allosteric mechanism. Taken together, these studies
demonstrate the versatility of single domain antibodies as
molecular probes to investigate kinase regulatorymechanisms.
However, vNAR-D01 does not bind Aurora-A with sufficient
affinity to be a useful tool in cell-based assays, which may
require a KD of less than 100 nM, and so we will affinity
mature this scaffold to improve its potency. In addition, to
avoid any potential folding issues of the inhibitor in a reducing
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8cellular environment, we will screen alternative, non-antibody
scaffolds that lack disulfide bonds.
3.2. Allosteric activators and inhibitors
vNAR-D01 inserts Trp91 into a hydrophobic pocket formed by
the aC-helix and strand b4 of Aurora-A. This pocket plays an
important role in the regulation of Aurora-A by TPX2, and
more generally in the regulation of AGC and related kinases,
through binding of a peptide bearing a hydrophobic motif
[40]. These interactions can be in cis, as in PKA, or in trans, as
in Aurora-A, or PDK1, and activate the kinase through stabiliz-
ation of an active conformation [41]. Specifically, the interaction
of TPX2 stabilizes the aC-helix of Aurora-A to ensure that the
Lys-Glu salt bridge is formed (figure 5). This regulatory, hydro-
phobic pocket presents an attractive target for the rational
development of allosteric kinase inhibitors. Indeed, the equiv-
alent hydrophobic (PIF) pocket of PDK1 has successfully been
targeted by small molecules, both directly and by tethering
approaches [6–8]. Here, we present an orthogonal approach
to targeting this pocket via a single domain antibody.
Although compounds based on the structure of Aurora-A in
complex with TPX2 would be expected to activate the kinase,
the Aurora-A/vNAR-D01 structure could form the basis for
rational design of allosteric inhibitors. More generally, we
believe that single domain antibodies will be useful to trap
kinases in an inactive conformation to facilitate the develop-
ment of allosteric kinase inhibitors, and will synergize with
other small molecule, peptide and computational approaches.
4. Material and methods
4.1. Cloning, protein expression and purification
The vectors pETM11 Aurora-A KD, pET30TEV Aurora-A KD
CA, pGEX-cs Aurora-A KD DN, pGEX-cs TPX21–43 and
pET30TEV TPX21–43 were produced in earlier work [17,42,43].
The vector pGEX-2T was used for the expression of GST. The
expression vector for Aurora-A KD-Avi was produced by sub-
cloning of the gene for Aurora-A KD into pETM6T1 for
expression with an N-terminal TEV cleavable His-NusA tag.
A C-terminal non-cleavable Avi-tag was added to the coding
sequencing of Aurora-A KD by primer extension PCR.
GST, TPX21–43 andAurora-AKD, KDCA andKDDNwere
expressed and purified as stated in earlier work [17,43]. The
expression vector for Aurora-A KD-Avi was co-transformed
into E. coli B834 cells with the vector pBirAcm for co-expression
with biotin ligase and cultured as recommended by the supplier
(Avidity LLC, USA). His-NusAAurora-A KD-Avi was purified
by immobilized metal ion affinity chromatography (IMAC)
using a HiTrap Chelating Sepharose HP column (GE Health-
care) as per the manufacturer’s instructions. The His-NusA
tag was removed by overnight TEV cleavage. IMAC was
repeated to remove the TEV protease, expression tag and
biotin ligase. Q-Sepharose chromatography (GE Healthcare)
was performed according to the manufacturer’s instructions
to improve protein purity. As a final polishing step, Aurora-A
KD-Avi was subject to SEC on a HiLoad 16/600 Superdex
200 column (GE Healthcare) equilibrated in 20 mM Tris pH
7.0, 200 mM NaCl, 5 mM MgCl2, 5 mM b-mercaptoethanol
and 10% glycerol. Biotinylation of purified Aurora-A KD-Avi
was confirmed by western blotting with an anti-biotin primary
antibody (abcam, 1 : 5000, ab53494).Expression vectors for vNAR constructs were transformed
into CodonPlus RIL E. coli cells and grown in LBmedia at 378C
until an induction OD600 approximately 0.6 was attained
and 0.6 mM IPTG added. Cultures were incubated overnight
at 218C prior to cell harvesting by centrifugation. Protein
purification was performed as described in other work for
His-tagged constructs [44]. The protein was subject to a final
SEC step as described for Aurora-A KD-Avi.
4.2. Crystal structure determination
To make the Aurora-A KD CA/vNAR-D01 complex, the pro-
teins were mixed at a stoichiometry of 1 : 1.2, respectively,
and were subject to SEC. Fractions containing complex were
combined and concentrated to 16.5 mg ml21, and incubated
with 5 mM ADP/MgCl2 for 1 h prior to crystallization screen-
ing trials. Screens were set up in 96-well sitting drop MRC
plates using a mosquito LCP crystallization robot (ttplabtech)
and incubated at 295 K. Crystals were observed after 2 days
of incubation in a number of conditions. Further hits were
identified in the following three weeks. Diffraction data were
collected at Diamond Light Source (Oxford, UK) on beamline
IO4-1. Two different space groups were observed and the
data from the highest resolution crystals were processed for
structure determination. Data used were from a single crystal.
Crystal form 1 was produced using 0.2 M ammonium sulfate,
0.1 M sodium acetate pH 4.6, 12.5% PEG 4000 as the mother
liquor. Crystal form 2 was grown using 0.2 M ammonium sul-
fate, 0.1 M bis-Tris pH 5.5, 25% PEG 3350 as a precipitant. Both
crystals were cryoprotected by the addition of 30% ethylene
glycol and flash-cooled. Data processing was carried out
using the ‘-3daii’ mode on the xia2 automated data reduction
platform available at Diamond Light Source. The structure of
Aurora-A KD CA/vNAR-D01 was solved by molecular repla-
cement using the structure of Aurora-A KD CA (PDB entry
4CEG) [31] and the structure of a Spotted Wobbegong shark
vNAR domain (PDB 2COQ) [45] as a model. The structure
was solved and rigid body refined with PHENIX. Model
building was carried out with COOT. MOLPROBITY was used for
Ramachandran analysis.
Crystals of Aurora-A KD CA/vNAR-D01 S93R were pro-
duced as for the WT complex using 0.1 M citric acid pH 5.0,
20% PEG 6000 as a precipitant and diffraction data were collec-
ted at Diamond Light Source on beamline IO4-1. Structure
determination was carried out as described above with data
from a single crystal cryoprotected in 30% ethylene glycol
using the WT complex crystal form 2 as a model.
4.3. Co-precipitation assays
For co-precipitation assays, 100 mg bait protein was immobi-
lized on 20 ml resin equilibrated in assay buffer. The resin was
pelleted by centrifugation and washed twice with assay
buffer. The beads were resuspended in assay buffer to
which 100 mg prey protein was added and incubated for a
further 2 h at 48C. The reactions were washed twice with
assay buffer prior to the addition of 20 ml SDS-loading
buffer and SDS-PAGE analysis. Glutathione Sepharose 4B
beads (GE Healthcare) equilibrated in the assay buffer,
50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM
b-mercaptoethanol and 0.02% TWEEN 20 were used in
assays where GST-Aurora-A KD DN and GST were used as
bait. Nickel Sepharose resin (GE Healthcare) equilibrated in
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9the assay buffer, 50 mM Tris pH 7.5, 150 mM NaCl, 40 mM
imidazole and 0.1% TWEEN-20 were used to immobilize
His6-Aurora-A KD CA and vNAR-D01 as bait proteins.
For competition co-precipitation assays performed with a
gradient of 0–50 mM His6-TPX2
1–43 and 5 mM vNAR-D01,
2 mMGST-Aurora-A KD DNwas immobilized on Glutathione
Sepharose 4B beads and reactions were performed as described
above.
4.4. In vitro kinase activity assays
Kinase assays were performed as stated in earlier work [43]. To
determine the IC50 of vNAR-D01 constructs, kinase reactions
were performed in the presence of 0–100 mM vNAR domain
and analysed by scintillation counting. Data were normalized
to % kinase activity using the Aurora-A KD only reaction as
100% and plotted against vNAR-D01 concentration. Data
were fitted to a log(inhibitor) versus response—variable
slope in PRISM6 (GraphPad) to calculate the IC50.
4.5. Surface plasmon resonance
SPR assays were performed on a BIAcore 3000 instrument
using running buffer, 10 mM Hepes pH 7.4, 150 mM NaCl,5 mM MgCl2, 10% glycerol and 0.005% TWEEN-20. Aurora-
A KD-Avi was immobilized on three flow-cells of BIAcore
SA sensor chips (GE Healthcare) at three immobilization
levels (250, 350 and 500 RU) and the fourth was left blank.
vNAR-D01 was diluted into running buffer to a range of con-
centrations and injected over the chips at 40 ml min21 for 375 s.
Sensorgrams were recorded for each injection and processed
using BIAEVALUATION 3.0 software (Biacore AB) and the data
recorded in the blank flow-cell subtracted from each sensor-
gram. Equilibrium response at 350 s was plotted against
concentration for each quantity of immobilized Aurora-A
KD-Avi and fitted by nonlinear regression to a binding
isotherm using PRISM6.
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